Clinical trialsCompany release

Roche to present trontinemab, NLRP3 inhibitor and pTau217 blood test data at CTAD 2026

Roche · Tue 10 Nov 2026

Roche will bring 16 abstracts to the CTAD Congress in Boston, spanning its brain-shuttle antibody, an oral NLRP3 inhibitor and its Elecsys blood-based Alzheimer's tests.

Roche said on 10 November 2026 that it will present data from 16 abstracts at the CTAD Congress in Boston, which runs from 16 to 19 November. The programme covers therapeutics and diagnostics in Alzheimer's disease.

For trontinemab, the company will show Phase Ib/IIa data generated with its Brainshuttle technology in Alzheimer's disease. It will also present the design of the Phase III PrevenTRON study, which is testing the molecule in preclinical Alzheimer's disease. Roche said enrolment in that trial has begun.

A second strand covers RG6434, an oral NLRP3 inhibitor. Roche will present the Phase II TARBELA-AD trial, which is investigating the compound in people with early symptomatic Alzheimer's disease.

On the diagnostics side, Roche will show clinical and health-economic data on its Elecsys pTau217 and pTau181 blood tests. The summary provided does not detail the specific results, endpoints or regulatory status of any of the products, so the substance of the findings will only become clear once the presentations take place.

What it means for your team

  • The PrevenTRON design and the start of enrolment signal that Roche is moving trontinemab into a preclinical-stage population, which will shape future evidence and labelling discussions.
  • Health-economic data on the Elecsys pTau217 and pTau181 blood tests are relevant to market-access teams assessing how biomarker testing might fit into Alzheimer's care pathways.
  • No efficacy, safety or regulatory details are available yet; teams should wait for the CTAD presentations before drawing conclusions.

Company's press release: Roche ↗

Article written by VigiEye from the official source (Roche). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →